EndoBridge 2024: pearls and highlights

Bulent Okan Yildiz¹, Eleni Armeni², Chrysanthi Balodimou³, Bernadette Biondi⁴, Andreea Ciudin^{5

6}, Gema Frühbeck⁷, Ghada El-Hajj Fuleihan⁸, Eliza B Geer⁹, Pieter Gillard¹⁰, Catherine M Gordon¹¹, Dimitrios Goulis³, Gary D Hammer¹², Charlotte Höybye¹³, Bente Lomholt Langdahl¹⁴, Alexandra B Laufer¹¹, A J van der Lely¹⁵, Djuro Macut¹⁶, Julia K Mader¹⁷, Barbara McGowan¹⁸, Eva Novac¹⁹, Duarte Pignatelli²⁰, Misa Pfeifer²¹, Lena Radić¹⁶, Viral Shah²², Constantine A Stratakis²³, Gerlies Treiber¹⁹, Dionysios N Vrachnis²⁴, John Wilding²⁵, Dilek Yazici²⁶, Ozlem Celik²⁷

Affiliations

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, 06100, Turkey. yildizbo@yahoo.com.
² Department of Endocrinology and NET Unit, Royal Free Hospital, London, UK.
³ Unit of Reproductive Endocrinology, First Department of Reproductive Endocrinology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
⁵ Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Endocrinology Department, Vall d'Hebron University Hospital, Autonomous University Barcelona, Barcelona, 08035, Spain.
⁶ CIBERDEM (Instituto de Salud Carlos III), Madrid, 28029, Spain.
⁷ Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, 31008, Spain.
⁸ Division of Endocrinology, Department of Medicine at the American, University of Beirut, Beirut, Lebanon.
⁹ Department of Medicine, Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Department of Endocrinology, KUL, and Senior Clinical investigator, University Hospitals Leuven, FWO, Leuven, Belgium.
¹¹ Section on Adolescent Bone & Body Composition, Eunice Kennedy Shriver Institute on Child Health and Human Development, Bethesda, MA, USA.
¹² Director of Endocrine Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
¹³ Department of Endocrinology, Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
¹⁴ Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
¹⁵ Pituitary Center Rotterdam and Division of Endocrinology, Department of Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
¹⁶ Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia.
¹⁷ Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
¹⁸ Consultant Endocrinologist and Professor of Diabetes and Endocrinology, Guy's and St Thomas Hospital and King's College London, London, UK.
¹⁹ Division of Endocrinology and Metabolism, Medical University Graz, Auenbruggerplatz 15, Graz, 8036, Austria.
²⁰ Hospital S. João and Department of Biomedicine, Faculty of Medicine of Porto, Porto, Portugal.
²¹ Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, 1000, Slovenia.
²² Division of Endocrinology & Metabolism, Indiana University School of Medicine, Indianapolis, IN, USA.
²³ Human Genetics & Precision Medicine, IMBB, FORTH, Heraklion, Greece.
²⁴ National and Kapodistrian University of Athens Medical School, Athens, Greece.
²⁵ Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
²⁶ Division of Endocrinology, Department of Internal Medicine, School of Medicine, Koç University, İstanbul, Turkey.
²⁷ Department of Endocrinology and Metabolism, School of Medicine, Acibadem University, Istanbul, Turkey.

PMID: 40768135
DOI: 10.1007/s42000-025-00708-5

Review

EndoBridge 2024: pearls and highlights

Bulent Okan Yildiz et al. Hormones (Athens). 2025.

. 2025 Aug 6.

doi: 10.1007/s42000-025-00708-5. Online ahead of print.

Authors

Affiliations

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, 06100, Turkey. yildizbo@yahoo.com.
² Department of Endocrinology and NET Unit, Royal Free Hospital, London, UK.
³ Unit of Reproductive Endocrinology, First Department of Reproductive Endocrinology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
⁵ Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Endocrinology Department, Vall d'Hebron University Hospital, Autonomous University Barcelona, Barcelona, 08035, Spain.
⁶ CIBERDEM (Instituto de Salud Carlos III), Madrid, 28029, Spain.
⁷ Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, 31008, Spain.
⁸ Division of Endocrinology, Department of Medicine at the American, University of Beirut, Beirut, Lebanon.
⁹ Department of Medicine, Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Department of Endocrinology, KUL, and Senior Clinical investigator, University Hospitals Leuven, FWO, Leuven, Belgium.
¹¹ Section on Adolescent Bone & Body Composition, Eunice Kennedy Shriver Institute on Child Health and Human Development, Bethesda, MA, USA.
¹² Director of Endocrine Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
¹³ Department of Endocrinology, Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
¹⁴ Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
¹⁵ Pituitary Center Rotterdam and Division of Endocrinology, Department of Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
¹⁶ Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia.
¹⁷ Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
¹⁸ Consultant Endocrinologist and Professor of Diabetes and Endocrinology, Guy's and St Thomas Hospital and King's College London, London, UK.
¹⁹ Division of Endocrinology and Metabolism, Medical University Graz, Auenbruggerplatz 15, Graz, 8036, Austria.
²⁰ Hospital S. João and Department of Biomedicine, Faculty of Medicine of Porto, Porto, Portugal.
²¹ Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, 1000, Slovenia.
²² Division of Endocrinology & Metabolism, Indiana University School of Medicine, Indianapolis, IN, USA.
²³ Human Genetics & Precision Medicine, IMBB, FORTH, Heraklion, Greece.
²⁴ National and Kapodistrian University of Athens Medical School, Athens, Greece.
²⁵ Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
²⁶ Division of Endocrinology, Department of Internal Medicine, School of Medicine, Koç University, İstanbul, Turkey.
²⁷ Department of Endocrinology and Metabolism, School of Medicine, Acibadem University, Istanbul, Turkey.

PMID: 40768135
DOI: 10.1007/s42000-025-00708-5

Abstract

EndoBridge 2024 was held from October 18-20, 2024, in Antalya, Türkiye. The scientific program of the 12th Annual Meeting of EndoBridge, accredited by the European Council, featured advanced lectures and interactive case discussion sessions in small groups, all delivered by internationally renowned experts in the field. The event attracted a wide range of attendees and offered an extensive overview of key topics in endocrinology and metabolism. These included pituitary, thyroid, bone, and adrenal diseases, neuroendocrine tumors, diabetes, obesity, nutrition, and lipid disorders. Abstracts of clinical cases presented during oral and poster sessions were published in JCEM Case Reports. This article summarizes the major highlights and key insights from the meeting, covering a broad spectrum of topics such as management of acromegaly, treatment of subclinical thyroid disease, goal-directed treatment for osteoporosis, the role of adjunctive therapies in type 1 diabetes mellitus, phenotyping obesities, hormonal management of menopause and premature ovarian failure, and updates on male hypogonadism and infertility. These discussions present the most recent advancements in endocrinology and offer clinical perspectives on prevalent endocrine conditions. The 13th Annual EndoBridge Meeting is scheduled to be held from October 23 to 26, 2025, in Antalya, Türkiye.

Keywords: Adrenal; Bone; Diabetes mellitus; Obesity; Pituitary; Thyroid.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: B.O.Y., O.C., DY, G.H, A.J.L., M.P, D.P, B.B., D.M., D.N.V., D.G., and C.B. have no relevant disclosures to report. V.S. has received research support from Alexion, Novo Nordisk, Dexcom, Breakthrough T1D, and NIH (NIDDK/NIAMS) and consulting, speaking, or advisory board from Dexcom, Insulet, Tandem Diabetes Care, Ascensia Diabetes Care, Embecta, Lilly, Sanofi, Novo Nordisk, Sequel Med Tech, Biomea Fusion, Lumosfit, and Genomelink. C.G. Present: Wolters Kluwer– royalties as textbook editor. Past: Gilead Sciences– consulting fees (for pediatric HIV bone density trial). J.K.M is a member of advisory boards of Abbott Diabetes Care, Biomea Fusion, Dexcom Inc., Boehringer Ingelheim, Eli Lilly, Embecta, Medtronic, Novo Nordisk A/S, Pharmasens, Roche Diabetes Care, and Sanofi-Aventis and received speaker honoraria from A. Menarini Diagnostics, Abbott Diabetes Care, Dexcom, Eli Lilly, Novo Nordisk A/S, Roche Diabetes Care, and Sanofi. She is shareholder of decide Clinical Software GmbH and Elyte Diagnostics and serves as CMO of Elyte Diagnostics. B.M was a PI in the SELECT trial. Else her interests are Reset Health shareholder Advisory Novo Nordisk, Lilly, Astra Zeneca Speaking bureau: Novo Nordisk, Lilly, and Amgen. B.L. has received research grants from Amgen, advisory boards, consultancy, and speaker bureaus from Amgen, UCB, Mereo, Samsung-Bioepis, Angitia, Entero-Bio, and Gideon-Richter. P.G. has received financial compensation from Medtronic in connection with preparing and delivering this presentation. E.G has commercial interest with Amryt/Chiesi; Recordati; Xeris; Corcept; Sparrow, Nature of Relationship: Institution-directed research support for clinical trial participation / Amryt/Chiesi; Crinetics; Xeris; HRA Pharma; Sparrow; Recordati; and Lundbeck, Nature of Relationship: Scientific Consulting/Advisory Boards. G.E.F. is a co-author of the ASBMR-BHOF Goal-Directed Osteoporosis Treatment position statement. G.F has received research grants to study obesity from competitive funding bodies: Fondo Investigación Sanitaria (FIS), CIBEROBN, and the Spanish Institute of Health & EU Funds. A.C. has received honoraria from Novo Nordisk, Eli Lilly, Astra Zeneca, Sanofi Aventis, ESTEVE, ZAMBON, and Boehringer Ingelheim, and Advisory Board from Eli Lilly, Novo Nordisk, and Boehringer Ingelheim. Data monitoring committee Boehringer Ingelheim. C.S. provides consulting services to STEROTHERAPEUTICS, Inc. and works with HUMAN LONGEVITY, ASTREA Health and Healthspan Digital, all private entities in the field of genetics. He has also received research support from Pfizer, Inc. All the above are unrelated to the content of this article. J.W reports consultancy / advisory board work for the pharmaceutical industry contracted via the University of Liverpool (no personal payment) for Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Cytoki, Lilly, Napp, Novo Nordisk, Menarini, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern, & Shionogi; research grants for clinical trials from AstraZeneca and Novo Nordisk and personal honoraria / lecture fees from AstraZeneca, Boehringer Ingelheim, Medscape, Novo Nordisk, and Rhythm. He is past president of the World Obesity Federation, a member of the Association for the Study of Obesity, Diabetes UK, EASD, ADA, Society for Endocrinology and the Rank Prize Funds Nutrition Committee. From 2009 to 2024 he was national lead for the Metabolic and Endocrine Specialty Group of the UK NIHR Clinical Research Network. E.A. is an advisory board member of Astellas and Besins Healthcare. C.H has received lecture fees from Novo Nordisk, Sandoz, and Pfizer. G.T has had a conflict of interest over the last 3 years regarding the topic “Lecture fees from Novo Nordisk, Medtronic, Sanofi.”

References

1. Yildiz BO, Boguszewski CL, da Silva Boguszewski MC, Busetto L, Celik O et al (2024) EndoBridge 2023: highlights and pearls hormones. (Athens) 23:183–204. https://doi.org/10.1007/s42000-024-00549-8 - DOI
1. Kamilaris CDC, Stratakis CA (2019) Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol (Lausanne) 10:339. https://doi.org/10.3389/fendo.2019.00339 - DOI - PubMed
1. Alrezk R, Hannah-Shmouni F, Stratakis CA (2017) MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer 24(10):T195–T208. https://doi.org/10.1530/ERC-17-0243 - DOI - PubMed - PMC
1. Stratakis CA, Kirschner LS, Carney JA (2001) Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 86(9):4041–4046. https://doi.org/10.1210/jcem.86.9.7903 - DOI - PubMed
1. Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO et al (2014) Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation. N Engl J Med 18;371(25):2363-74. https://doi.org/10.1056/NEJMoa1408028

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Springer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

EndoBridge 2024: pearls and highlights

Affiliations

EndoBridge 2024: pearls and highlights

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

LinkOut - more resources

Full Text Sources